Receiving a notice from Nasdaq about failing to meet the minimum bid price requirement is a significant negative development for any listed company. It puts the company at risk of being delisted, which can severely impact its stock price and investor confidence. For Endra Life Sciences, this news directly affects its standing on the Nasdaq Capital Market and could lead to a decrease in its stock price in the short term as investors react to the potential delisting risk.